Miguel Hernández University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Elche Spain (1996)

Organization Overview

First Clinical Trial
1999
NCT00004150
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Garcilaso Clinic | Hospital de Elche | Hospital General de Elche | Hospital general Elche | Hospital General Univeristario de Elche | Hospital General Universitario de Elche | Hospital General Universitario Elche | Hospital Gnral de Elche | Hospital Universitario de Elche | Hosptial General Universitario de Elche | Unidad Enfermedades Infecciosas, Hospital General Univeristario de Elche | UNIVERSIDAD MIGUEL HERNANDEZ | Universidad Miguel Hernández | Universidad Miguel Hernandez de Elche | Universidad Miguel Hernandez, Elche, Spain

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Anemia, Iron-Deficiency (Phase 3)

Breast Neoplasms (Phase 3)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 2)

Fissure in Ano (Phase 3)

Hemorrhoids (Phase 3)

Infections (Phase 3)

Lung Neoplasms (Phase 2)

Lymphopenia (Phase 2)

Pain, Postoperative (Phase 3)

Pneumonia (Phase 4)

Rectal Neoplasms (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Surgical Wound Infection (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 37